CBD & human evidence
CBD and nerve pain: what small human studies actually found
A balanced review of topical peripheral-neuropathy research, negative oral arthritis trials and why one customer story cannot establish a 100% result.
One small topical trial reported symptom improvements; larger or different oral trials found no additional analgesic benefit. None tested Enki’s finished blend.
Compounds & molecular formulae
CBD
C₂₁H₃₀O₂
The compound studied in the trials below; study dose, route and product composition matter.
PubChem compound record ↗7-hydroxy-CBD
C₂₁H₃₀O₃
An active metabolite reported in pharmacokinetic research; metabolites complicate simple “one molecule, one effect” claims.
PubChem compound record ↗From a nerve symptom to a clinical endpoint
- Nerve injury changes peripheral signalling
- A formulation reaches its intended tissue
- Sensory pathways and perception may change
- A validated pain scale tests the net result
Only the measured patient endpoint can tell us whether the proposed mechanism translated into benefit [1][2][3].
The positive signal: a small topical trial
Xu and colleagues randomised 29 people with symptomatic peripheral neuropathy of the lower extremities to a topical preparation containing 250 mg CBD per 3 fluid ounces or placebo for four weeks [1]. The CBD group had statistically significant reductions in intense pain, sharp pain, cold and itchy sensations, and no adverse events were reported in that small study. It is a useful signal, but it has important boundaries: the sample was small, the study was short, the product and concentration were specified, and the results do not establish that every topical or oral CBD oil will work the same way.
The negative signals: arthritis trials
In a 136-person randomised double-blind trial, participants with hand osteoarthritis or psoriatic arthritis received synthetic CBD 20–30 mg daily or placebo for 12 weeks. The between-group pain difference was 0.23 mm on a 0–100 mm scale, with no clinically or statistically significant effect [2]. A separate randomised knee-osteoarthritis trial tested high-dose oral CBD 600 mg/day as an add-on to paracetamol; pain improved in both groups but not more with CBD, while adverse events and liver-enzyme rises were more frequent with CBD [3]. These findings directly challenge broad claims that oral CBD is a proven analgesic.
Why route and formulation matter
Topical application, oral swallowing and prescription oral solution create different concentrations at skin, blood, liver and nervous tissue. A study of a defined topical product cannot validate an untested blend containing essential oils. A prescription trial cannot be used to infer a retail dose. Outcomes also depend on the diagnosis: “nerve issue” can describe diabetic neuropathy, compression, vitamin deficiency, medication toxicity or another condition requiring assessment. Persistent weakness, numbness, loss of balance or bladder changes deserve prompt clinical evaluation.
How to use the evidence responsibly
The customer feedback displayed on this site says: “The CBD Oil was magical for my mother. The nerve issue have disappeared 100%.” It is an individual experience supplied to Enki, not an independently verified clinical outcome, and it does not predict another person’s result. We keep it separate from Google reviews and label it as a customer story. Ask the Enki team for the current label, CBD amount and directions; ask a qualified clinician about suitability and interactions.
Sources & credits
- Xu et al. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy (Current Pharmaceutical Biotechnology, 2020) — Small randomised topical trial
- Vela et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis (Pain, 2022) — Randomised double-blind placebo-controlled trial
- Schimkowski et al. Oral cannabidiol as add-on to paracetamol for painful chronic knee osteoarthritis (The Lancet Regional Health – Europe, 2023) — Randomised double-blind placebo-controlled trial